The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drug ALK Inhibitors for NSCLC Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Targeted Drug ALK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drug ALK Inhibitors for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drug ALK Inhibitors for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Crizotinib segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drug ALK Inhibitors for NSCLC include Pfizer, Novartis, Chugai Pharmaceutical (Hoffmann-La Roche group), ARIAD Pharmaceuticals (Takeda), and Genvio Pharma Limited, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drug ALK Inhibitors for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Pfizer
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drug ALK Inhibitors for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drug ALK Inhibitors for NSCLC, with revenue, gross margin and global market share of Targeted Drug ALK Inhibitors for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drug ALK Inhibitors for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drug ALK Inhibitors for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drug ALK Inhibitors for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
The Targeted Drug ALK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Targeted Drug ALK Inhibitors for NSCLC market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Squamous Cell Carcinoma of NSCLC accounting for % of the Targeted Drug ALK Inhibitors for NSCLC global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Crizotinib segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Targeted Drug ALK Inhibitors for NSCLC include Pfizer, Novartis, Chugai Pharmaceutical (Hoffmann-La Roche group), ARIAD Pharmaceuticals (Takeda), and Genvio Pharma Limited, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Targeted Drug ALK Inhibitors for NSCLC market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Pfizer
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Targeted Drug ALK Inhibitors for NSCLC product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Targeted Drug ALK Inhibitors for NSCLC, with revenue, gross margin and global market share of Targeted Drug ALK Inhibitors for NSCLC from 2019 to 2022.
Chapter 3, the Targeted Drug ALK Inhibitors for NSCLC competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Targeted Drug ALK Inhibitors for NSCLC market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Targeted Drug ALK Inhibitors for NSCLC research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Targeted Drug ALK Inhibitors for NSCLC
1.2 Classification of Targeted Drug ALK Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type in 2021
1.2.3 Crizotinib
1.2.4 Ceritinib
1.2.5 Alectinib
1.2.6 Brigatinib
1.2.7 Lorlatinib
1.2.8 Other
1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region, (2017-2022)
1.5.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.6 South America Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug ALK Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug ALK Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.1.4 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.2.4 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
2.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Details
2.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Major Business
2.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments and Future Plans
2.4 ARIAD Pharmaceuticals (Takeda)
2.4.1 ARIAD Pharmaceuticals (Takeda) Details
2.4.2 ARIAD Pharmaceuticals (Takeda) Major Business
2.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.4.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
2.5 Genvio Pharma Limited
2.5.1 Genvio Pharma Limited Details
2.5.2 Genvio Pharma Limited Major Business
2.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.5.4 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Genvio Pharma Limited Recent Developments and Future Plans
2.6 Beacon Pharma Limited
2.6.1 Beacon Pharma Limited Details
2.6.2 Beacon Pharma Limited Major Business
2.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.6.4 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Beacon Pharma Limited Recent Developments and Future Plans
2.7 Drug International Limted
2.7.1 Drug International Limted Details
2.7.2 Drug International Limted Major Business
2.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.7.4 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Drug International Limted Recent Developments and Future Plans
2.8 Incepta Pharmaceuticals
2.8.1 Incepta Pharmaceuticals Details
2.8.2 Incepta Pharmaceuticals Major Business
2.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.8.4 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Incepta Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug ALK Inhibitors for NSCLC Players Market Share in 2021
3.2.2 Top 10 Targeted Drug ALK Inhibitors for NSCLC Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Targeted Drug ALK Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Targeted Drug ALK Inhibitors for NSCLC Mergers & Acquisitions
3.5 Targeted Drug ALK Inhibitors for NSCLC New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Type (2017-2022)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2017-2022)
5.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2028)
6.2 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2028)
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2028)
6.3.2 United States Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
6.3.3 Canada Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
6.3.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2028)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2028)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2028)
7.3.2 Germany Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.3 France Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.5 Russia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
7.3.6 Italy Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2028)
8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2028)
8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2017-2028)
8.3.2 China Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.3 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.4 South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.5 India Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
8.3.7 Australia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2028)
9.2 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2028)
9.3 South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2028)
9.3.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
9.3.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2028)
10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2028)
10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2028)
10.3.2 Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
10.3.4 UAE Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Region (2017-2022)
Table 5. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2023-2028)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 9. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 13. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Chugai Pharmaceutical (Hoffmann-La Roche group) Corporate Information, Head Office, and Major Competitors
Table 15. Chugai Pharmaceutical (Hoffmann-La Roche group) Major Business
Table 16. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 17. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. ARIAD Pharmaceuticals (Takeda) Corporate Information, Head Office, and Major Competitors
Table 19. ARIAD Pharmaceuticals (Takeda) Major Business
Table 20. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 21. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Genvio Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 23. Genvio Pharma Limited Major Business
Table 24. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 25. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 27. Beacon Pharma Limited Major Business
Table 28. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 29. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Drug International Limted Corporate Information, Head Office, and Major Competitors
Table 31. Drug International Limted Major Business
Table 32. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 33. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Incepta Pharmaceuticals Major Business
Table 36. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 37. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 39. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 40. Breakdown of Targeted Drug ALK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Targeted Drug ALK Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 42. Targeted Drug ALK Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 43. Targeted Drug ALK Inhibitors for NSCLC New Entrants and Expansion Plans
Table 44. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Type (2017-2022)
Table 45. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2017-2022)
Table 46. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Type (2023-2028)
Table 47. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022)
Table 48. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Application (2023-2028)
Table 49. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 50. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 51. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 52. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 53. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 54. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 55. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 56. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 57. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 58. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 59. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 60. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 61. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 62. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 63. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 64. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 65. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2017-2022) & (USD Million)
Table 66. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2023-2028) & (USD Million)
Table 67. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 68. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 69. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 70. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 71. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 72. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
Table 73. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2017-2022) & (USD Million)
Table 74. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2023-2028) & (USD Million)
Table 75. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2017-2022) & (USD Million)
Table 76. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2023-2028) & (USD Million)
Table 77. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2017-2022) & (USD Million)
Table 78. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Targeted Drug ALK Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type in 2021
Figure 3. Crizotinib
Figure 4. Ceritinib
Figure 5. Alectinib
Figure 6. Brigatinib
Figure 7. Lorlatinib
Figure 8. Other
Figure 9. Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application in 2021
Figure 10. Squamous Cell Carcinoma of NSCLC Picture
Figure 11. Adenocarcinoma of NSCLC Picture
Figure 12. Large Cell Carcinoma of NSCLC Picture
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2017-2028)
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region in 2021
Figure 17. North America Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
Figure 23. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
Figure 24. Targeted Drug ALK Inhibitors for NSCLC Market Trends
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments and Future Plans
Figure 28. ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
Figure 29. Genvio Pharma Limited Recent Developments and Future Plans
Figure 30. Beacon Pharma Limited Recent Developments and Future Plans
Figure 31. Drug International Limted Recent Developments and Future Plans
Figure 32. Incepta Pharmaceuticals Recent Developments and Future Plans
Figure 33. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2021
Figure 34. Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2021
Figure 36. Global Top 10 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type in 2021
Figure 39. Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Type (2023-2028)
Figure 40. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application in 2021
Figure 41. Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Application (2023-2028)
Figure 42. North America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 43. North America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 44. North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 45. United States Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 49. Europe Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 50. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 51. Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2017-2028)
Figure 59. China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 66. South America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 67. South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
